Can I take Paxlovid (nirmatrelvir/ritonavir) for COVID-19 while taking Repatha (evolocumab)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 4, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Paxlovid Can Be Taken While on Repatha for COVID-19 Treatment

Yes, you can take Paxlovid (nirmatrelvir/ritonavir) for COVID-19 while taking Repatha (evolocumab). There are no significant drug interactions between these medications that would prevent their concurrent use 1.

Rationale for Using Paxlovid

Paxlovid is strongly recommended for COVID-19 patients at high risk of hospitalization, with evidence showing:

  • Significant reduction in hospitalization risk by 39% and death risk by 61% in recent real-world data 2
  • High effectiveness in preventing progression to severe COVID-19 when started within 5 days of symptom onset 3, 4
  • Better outcomes when initiated early in the disease course, making prompt treatment crucial 3

Administration Guidelines

  • Start Paxlovid as soon as possible after COVID-19 diagnosis and within 5 days of symptom onset 3, 1
  • Standard dosage: 300 mg nirmatrelvir (two 150 mg tablets) with 100 mg ritonavir (one 100 mg tablet), taken together twice daily for 5 days 1
  • Can be taken with or without food 1
  • Dose adjustments are required for patients with moderate to severe renal impairment 1

Drug Interaction Considerations

While Repatha (evolocumab) does not have significant interactions with Paxlovid, it's important to note:

  • Ritonavir is a potent CYP3A inhibitor that can interact with many medications 1, 5
  • Before starting Paxlovid, all current medications should be reviewed for potential interactions 1
  • Particular caution is needed with medications highly dependent on CYP3A for clearance 1
  • No specific interactions between Paxlovid and PCSK9 inhibitors like Repatha have been reported 5

Special Considerations

  • Paxlovid has shown effectiveness in both vaccinated and unvaccinated individuals 2
  • Older adults (65+ years) show greater absolute risk reduction with Paxlovid treatment 2
  • Patients with comorbidities may experience significant improvement in oxygen saturation within 24 hours of starting treatment 6
  • Monitoring for adverse effects is recommended, with dysgeusia (taste disturbance) and diarrhea being the most common side effects 1

Potential Pitfalls to Avoid

  • Delaying treatment beyond 5 days of symptom onset significantly reduces effectiveness 3
  • Failing to adjust dosage in patients with renal impairment could lead to toxicity 1
  • Not completing the full 5-day course may reduce effectiveness 1
  • Overlooking other medications that might interact with Paxlovid's ritonavir component 5

Conclusion

Taking Paxlovid while on Repatha is appropriate for COVID-19 treatment. The benefits of Paxlovid in reducing hospitalization and death risk outweigh potential concerns, especially when started early in the disease course. No dose adjustments are needed for Repatha when taking Paxlovid 1, 5.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.